{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T10:25:19Z","timestamp":1776939919995,"version":"3.51.4"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ijcard.2023.03.023","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T20:41:39Z","timestamp":1678480899000},"page":"40-47","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Safety and efficacy of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation electrical cardioversion: An update systematic review and meta-analysis"],"prefix":"10.1016","volume":"379","author":[{"given":"Federica","family":"Troisi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Guida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Vitulano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federico","family":"Quadrini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio","family":"Di Monaco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.ijcard.2023.03.023_bb0005","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1161\/CIRCULATIONAHA.113.005119","article-title":"Worldwide epidemiology of atrial fibrillation: a global burden of disease 2010 study","volume":"129","author":"Chugh","year":"2014","journal-title":"Circulation."},{"issue":"5","key":"10.1016\/j.ijcard.2023.03.023_bb0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/eurheartj\/ehaa612","volume":"42","author":"Hindricks","year":"2021","journal-title":"Eur. Heart J."},{"issue":"16","key":"10.1016\/j.ijcard.2023.03.023_bb0015","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"issue":"12","key":"10.1016\/j.ijcard.2023.03.023_bb0020","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ijcard.2023.03.023_bb0025","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ijcard.2023.03.023_bb0030","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.ahj.2015.07.006","volume":"170","author":"Bansilal","year":"2015","journal-title":"Am. Heart J."},{"issue":"5","key":"10.1016\/j.ijcard.2023.03.023_bb0035","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial","volume":"5","author":"Kato","year":"2016","journal-title":"J. Am. Heart Assoc."},{"issue":"47","key":"10.1016\/j.ijcard.2023.03.023_bb0040","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1093\/eurheartj\/ehu367","article-title":"Rivaroxaban vs. vitamin K antagonists for cardioversion in atrial fibrillation","volume":"35","author":"Cappato","year":"2014","journal-title":"Eur. Heart J."},{"issue":"10055","key":"10.1016\/j.ijcard.2023.03.023_bb0045","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/S0140-6736(16)31474-X","article-title":"Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial","volume":"388","author":"Goette","year":"2016","journal-title":"Lancet."},{"issue":"32","key":"10.1016\/j.ijcard.2023.03.023_bb0050","doi-asserted-by":"crossref","first-page":"2959","DOI":"10.1093\/eurheartj\/ehy148","article-title":"Apixaban compared to heparin\/vitamin K antagonist in patients with atrial fibrillation scheduled for cardioversion: the EMANATE trial","volume":"39","author":"Ezekowitz","year":"2018","journal-title":"Eur. Heart J."},{"issue":"4","key":"10.1016\/j.ijcard.2023.03.023_bb0055","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1007\/s11239-018-1622-5","article-title":"Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis","volume":"45","author":"Brunetti","year":"2018","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.ijcard.2023.03.023_bb0060","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.ijcard.2018.04.034","article-title":"Non-vitamin K antagonists oral anticoagulants are as safe and effective as warfarin for cardioversion of atrial fibrillation: a systematic review and meta-analysis","volume":"268","author":"Telles-Garcia","year":"2018","journal-title":"Int. J. Cardiol."},{"issue":"3","key":"10.1016\/j.ijcard.2023.03.023_bb0065","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s10557-019-06869-x","article-title":"Direct oral anticoagulants versus vitamin K antagonists in patients undergoing cardioversion for atrial fibrillation: a systematic review and meta-analysis","volume":"33","author":"Gupta","year":"2019","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"1","key":"10.1016\/j.ijcard.2023.03.023_bb0070","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients","volume":"8","author":"Schulman","year":"2010","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2023.03.023_bb0075","series-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration","article-title":"Chapter 8: Assessing risk of bias in included studies","author":"Higgins","year":"2011"},{"issue":"9","key":"10.1016\/j.ijcard.2023.03.023_bb0080","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur. J. Epidemiol."},{"issue":"6","key":"10.1016\/j.ijcard.2023.03.023_bb0085","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/jrsm.1460","article-title":"Zero-cell corrections in random-effects meta-analyses","volume":"11","author":"Weber","year":"2020","journal-title":"Res. Synth. Methods"},{"issue":"22","key":"10.1016\/j.ijcard.2023.03.023_bb0090","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1002\/(SICI)1097-0258(19981130)17:22<2537::AID-SIM953>3.0.CO;2-C","article-title":"Meta-analysis of multiple outcomes by regression with random effects","volume":"17","author":"Berkey","year":"1998","journal-title":"Stat. Med."},{"issue":"2","key":"10.1016\/j.ijcard.2023.03.023_bb0095","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.110.977546","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion","volume":"123","author":"Nagarakanti","year":"2011","journal-title":"Circulation."},{"issue":"12","key":"10.1016\/j.ijcard.2023.03.023_bb0100","first-page":"1541","article-title":"Comparison of outcomes after cardioversion or atrial fibrillation ablation in patients with differing periprocedural anticoagulation regimens","volume":"30","author":"Kochh\u00e4user","year":"2014","journal-title":"Can. J. Cardiol."},{"key":"10.1016\/j.ijcard.2023.03.023_bb0105","first-page":"1","article-title":"Real world usage of oral anticoagulants in patients undergoing electrical cardioversion for atrial tachyarrhythmias","volume":"31","author":"Carrizo","year":"2015","journal-title":"Can. J. Cardiol."},{"issue":"6","key":"10.1016\/j.ijcard.2023.03.023_bb0110","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/pace.12618","article-title":"Novel oral anticoagulants for DC cardioversion procedures: utilization and clinical outcomes compared with warfarin","volume":"38","author":"Coleman","year":"2015","journal-title":"Pacing Clin. Electrophysiol."},{"issue":"10","key":"10.1016\/j.ijcard.2023.03.023_bb0115","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141377","article-title":"Cardioversion and risk of adverse events with dabigatran versus warfarin-a nationwide cohort study","volume":"10","author":"Pallisgaard","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ijcard.2023.03.023_bb0120","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s40119-016-0067-1","article-title":"Dabigatran versus warfarin for direct current cardioversion in atrial fibrillation","volume":"5","author":"Benamer","year":"2016","journal-title":"Cardiol. Ther."},{"issue":"6","key":"10.1016\/j.ijcard.2023.03.023_bb0125","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1002\/clc.22537","article-title":"Cardioversion of atrial fibrillation in ENGAGE AF-TIMI 48","volume":"39","author":"Plitt","year":"2016","journal-title":"Clin. Cardiol."},{"issue":"1","key":"10.1016\/j.ijcard.2023.03.023_bb0130","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.joa.2016.04.003","article-title":"Non-vitamin K antagonist oral anticoagulants versus warfarin for cardioversion of atrial fibrillation in clinical practice: a single-center experience","volume":"33","author":"Shibata","year":"2017","journal-title":"J. Arrhythm."},{"issue":"7","key":"10.1016\/j.ijcard.2023.03.023_bb0135","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.hlc.2017.06.726","article-title":"Novel Oral anticoagulants in direct current cardioversion for atrial fibrillation","volume":"27","author":"Femia","year":"2018","journal-title":"Heart Lung Circ."},{"issue":"7","key":"10.1016\/j.ijcard.2023.03.023_bb0140","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1093\/europace\/eux188","article-title":"Cardioversion of atrial fibrillation in a real-world setting: non-vitamin K antagonist oral anticoagulants ensure a fast and safe strategy compared to warfarin","volume":"20","author":"Frederiksen","year":"2018","journal-title":"Europace."},{"issue":"7","key":"10.1016\/j.ijcard.2023.03.023_bb0145","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.amjcard.2018.06.022","article-title":"Outcomes with novel oral anticoagulants in obese patients who underwent electrical cardioversion for atrial tachyarrhythmias","volume":"122","author":"Kaplan","year":"2018","journal-title":"Am. J. Cardiol."},{"issue":"2","key":"10.1016\/j.ijcard.2023.03.023_bb0150","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s11239-017-1599-5","article-title":"Efficacy and safety of dabigatran in patients with atrial fibrillation scheduled for transoesophageal echocardiogram-guided direct electrical current cardioversion: a prospective propensity score-matched cohort study","volume":"45","author":"Russo","year":"2018","journal-title":"J. Thromb. Thrombolysis"},{"issue":"4","key":"10.1016\/j.ijcard.2023.03.023_bb0155","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40256-019-00341-9","article-title":"Clinical performance of apixaban vs. vitamin K antagonists in patients with atrial fibrillation undergoing direct electrical current cardioversion: a prospective propensity score-matched cohort study","volume":"19","author":"Rago","year":"2019","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"5","key":"10.1016\/j.ijcard.2023.03.023_bb0160","doi-asserted-by":"crossref","DOI":"10.1111\/anec.12766","article-title":"Real-life experience with non-vitamin K antagonist oral anticoagulants versus warfarin in patients undergoing elective cardioversion of atrial fibrillation","volume":"25","author":"It\u00e4inen-Str\u00f6mberg","year":"2020","journal-title":"Ann. Noninvasive Electrocardiol."},{"key":"10.1016\/j.ijcard.2023.03.023_bb0165","doi-asserted-by":"crossref","first-page":"6","DOI":"10.33678\/cor.2020.063","article-title":"Efficacy and safety of non-vitamin K antagonist oral anticoagulants one year after electrical cardioversion","volume":"63","author":"Berzins","year":"2021","journal-title":"Cor Vasa"},{"key":"10.1016\/j.ijcard.2023.03.023_bb0170","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.ijcard.2020.10.070","article-title":"Efficacy and safety of direct oral anticoagulants in patients undergoing elective electrical cardioversion: a real-world patient population","volume":"326","author":"de Heide","year":"2021","journal-title":"Int. J. Cardiol."},{"issue":"8","key":"10.1016\/j.ijcard.2023.03.023_bb0175","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1136\/heartjnl-2019-316315","article-title":"Patterns of oral anticoagulation use with cardioversion in clinical practice","volume":"107","author":"Geurink","year":"2021","journal-title":"Heart."},{"issue":"5","key":"10.1016\/j.ijcard.2023.03.023_bb0180","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s10557-020-07078-7","article-title":"Direct current cardioversion in atrial fibrillation patients on edoxaban therapy versus vitamin K antagonists: a real-world propensity score-matched study","volume":"35","author":"Rago","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"issue":"2","key":"10.1016\/j.ijcard.2023.03.023_bb0185","doi-asserted-by":"crossref","first-page":"88","DOI":"10.14740\/cr1352","article-title":"Trends and outcomes of oral anticoagulation with direct current cardioversion for atrial fibrillation\/flutter at an academic medical center","volume":"13","author":"Arshad","year":"2022","journal-title":"Cardiol. Res."},{"issue":"22","key":"10.1016\/j.ijcard.2023.03.023_bb0190","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxabanversus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijcard.2023.03.023_bb0195","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.amjcard.2020.06.046","article-title":"Differences in thromboembolic complications between paroxysmal and persistent atrial fibrillation patients following electrical cardioversion (from the ENSURE-AF study)","volume":"131","author":"Goette","year":"2020","journal-title":"Am. J. Cardiol."},{"issue":"11","key":"10.1016\/j.ijcard.2023.03.023_bb0200","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1007\/s00392-020-01635-8","article-title":"Effect of concomitant antiplatelet agents on clinical outcomes in the edoxaban vs warfarin in subjects undergoing cardioversion of atrial fibrillation (ENSURE-AF) randomized trial","volume":"109","author":"Goette","year":"2020","journal-title":"Clin. Res. Cardiol."},{"issue":"10","key":"10.1016\/j.ijcard.2023.03.023_bb0205","doi-asserted-by":"crossref","first-page":"e604","DOI":"10.1161\/CIR.0000000000000477","article-title":"Management of patients on non-vitamin K antagonist oral anticoagulants in the acute care and periprocedural setting: a scientific statement from the American Heart Association","volume":"135","author":"Raval","year":"2017","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2023.03.023_bb0210","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2147\/PPA.S131158","article-title":"Real-life experience of quality of life, treatment satisfaction, and adherence in patients receiving oral anticoagulants for atrial fibrillation","volume":"12","author":"Benzimra","year":"2018","journal-title":"Patient Prefer Adherence"},{"issue":"12","key":"10.1016\/j.ijcard.2023.03.023_bb0215","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1093\/europace\/euy141","article-title":"Edoxaban therapy increases treatment satisfaction and reduces utilization of healthcare resources: an analysis from the EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of atrial fibrillation (ENSURE-AF) study","volume":"20","author":"Goette","year":"2018","journal-title":"Europace."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527323003947?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527323003947?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T21:00:20Z","timestamp":1759093220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527323003947"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":43,"alternative-id":["S0167527323003947"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2023.03.023","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation electrical cardioversion: An update systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2023.03.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}